Trial ID or NCT#

NCT01019148

Status

recruiting iconRECRUITING

Purpose

Dystrophic epidermolysis bullosa (DEB) is a group of diseases caused by genetic mutations in the gene for type VII collagen. DEB can be severe or mild with the recessive disease usually being more severe. Patients with DEB develop large, severely painful blisters and open wounds from minor trauma to their skin. We are screening subjects with DEB to evaluate characteristics of the subjects and their cells in order to develop new strategies of therapy.

Official Title

Characteristics of Patients With Recessive Dystrophic Epidermolysis Bullosa

Eligibility Criteria

Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Jean Y. Tang MD PhD
Jean Y. Tang MD PhD
General dermatologist, Dermatologic oncologist, Cutaneous oncology specialist
Professor of Dermatology at the Stanford University Medical Center
Paul A. Khavari, MD, PhD
Paul A. Khavari, MD, PhD
Dermatologist, Cutaneous oncology specialist, Medical oncologist
Carl J. Herzog Professor in Dermatology in the School of Medicine
Anthony Oro, MD, PhD
Anthony Oro, MD, PhD
Hair loss specialist, Dermatologic oncologist, Cutaneous oncology specialist, Skin stem cell specialist
Eugene and Gloria Bauer Professor
M. Peter Marinkovich, MD
M. Peter Marinkovich, MD
Dermatologist, Blistering disease specialist, Psoriasis specialist
Associate Professor of Dermatology
Marius Wernig

Contact us to find out if this trial is right for you.

CONTACT

Kylie Loutit, BS
(650) 721-7166